Parexel Partners in Early-Phase Research with UH Bristol
Parexel yesterday announced that they have extended their alliance network for early-phase research by partnering with University Hospitals Bristol National Health Service Foundation Trust (UH Bristol), which is one of the UK’s biggest specialist training and research hospital trusts.
With this arrangement Parexel continues to increase their network, which complements the US-based biopharmaceutical services company’s hospital-based early-phase units in Berlin, Baltimore and Glendale, Bloemfontein and London.
UH Bristol is the main supplier of medical and dental teaching in South West England, with a leading research centre and one of the principal acute NHS Trusts in the UK, Parexel observed. It provides over 100 different clinical services from nine different hospitals in the heart of Bristol.
The corporate vice president and worldwide head of Early Phase, Sy Pretorius, commented that the UH Bristol is an “ideal” partnership for Parexel as a result of the trust’s “experience in conducting clinical research, access to substantial patient populations, and work across multiple therapeutic areas.”
Parexel’s Early Phase unit assists clients with the proposal and implementation of early-phase research studies from first-in-human through to proof-of-concept, providing clients with access to different patient populations globally in important therapeutic areas.
“We believe this alliance furthers our objectives to develop collaborative and consultative research partnerships and support research of national and international excellence and innovation,” added Professor David Wynick, research director at UH Bristol.